Finerenone use for 6 months was safe and associated with a significant 25% decrease in albuminuria for adults with type 1 diabetes and chronic kidney disease, according to data presented in the ...

Vanda Pharmaceuticals Inc. (Vanda) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 15, 2026.  A corporate ...

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.

The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.

Learn more about whether Nurix Therapeutics, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Dr Pietro A. Canetta illustrates recent advances in IgA nephropathy and focal segmental glomerulosclerosis (FSGS) with two ...

Jeff Johnston, Amanda Stewart, Anita Berry and Lauren Lange represented 64 clients in Q3. The Hillsborough County Sheriff’s ...

Renalys Pharma reports positive results from phase III study of sparsentan in Japanese patients with IgA nephropathy: Tokyo, Japan Friday, November 28, 2025, 13:00 Hrs [IST] Renal ...

In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine ...

Travere Therapeutics Inc. has reached a new 52-week high, with its stock price climbing to 36.81 USD. This milestone reflects a significant upward trend for the company, which has experienced a ...

New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares ...